Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL

Category Primary study
JournalJournal of Clinical Oncology
Year 2014
This article has no abstract
Epistemonikos ID: 1ee96666d5d07f53f978a04e31c1389b1182088f
First added on: Feb 06, 2025